Neil Stahl, EVP Research and Development at REGENERON PHARMACEUTICALS INC (REGN), sold 10,544 shares at $466.33 ($4.9M) on 2017-06-02, disclosed to the SEC on 2017-06-05.
Open-market sale of $4.9M REGN by EVP Research and Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $464.98 | 1,068 | $497K | 10.0% |
| 2 | $464.98 | 1,885 | $876K | 17.7% |
| 3 | $464.98 | 2,167 | $1.0M | 20.4% |
| 4 | $464.98 | 2,612 | $1.2M | 24.6% |
| 5 | $466.33 | 100 | $47K | 0.9% |
| 6 | $469.83 | 100 |
| $47K |
| 1.0% |
| 7 | $470.49 | 100 | $47K | 1.0% |
| 8 | $472.10 | 100 | $47K | 1.0% |
| 9 | $474.82 | 100 | $47K | 1.0% |
| 10 | $475.33 | 100 | $48K | 1.0% |
| 11 | $476.52 | 100 | $48K | 1.0% |
| 12 | $479.00 | 100 | $48K | 1.0% |
| 13 | $480.71 | 309 | $149K | 3.0% |
| 14 | $481.64 | 695 | $335K | 6.8% |
| 15 | $482.56 | 808 | $390K | 7.9% |
| 16 | $483.42 | 200 | $97K | 2.0% |
| Total | $468.85 avg | 10,544 | $4.9M | 100% |
| Filing → |
| REGN | SELL | 2023-08-23 | $19.6M | — | Filing → |
| REGN | SELL | 2022-08-08 | $28.4M | — | Filing → |
| REGN | SELL | 2021-05-18 | $18.2M | — | Filing → |